NextFin News - Aqua Bio Technology ASA (ABTEC) revealed on Friday that its subsequent offering has met with a lukewarm reception from the market, securing subscriptions for less than half of the available shares. Preliminary results show that the Oslo-listed biotech and skincare group received valid subscriptions for 388,240 new shares, representing just 48.5% of the 800,000 shares on offer. At a fixed price of NOK 5.00 per share, the exercise is set to raise approximately NOK 1.94 million, falling significantly short of the NOK 4 million maximum target.
The subscription period, which closed on March 19, was designed as a "repair issue" to allow shareholders who were excluded from a larger private placement in February to maintain their relative ownership. That earlier placement was a far more substantial affair, involving a NOK 50 million conversion of seller credit related to the acquisition of Jetcarrier. The disparity between the success of the institutional-led private placement and the retail-focused subsequent offering suggests a disconnect between the company’s aggressive expansion strategy and the appetite of its broader shareholder base.
Under the leadership of CEO and CFO Kristian Flaten, ABTEC has been pivoting from a pure-play biotechnology developer into a vertically integrated distribution powerhouse. The acquisition of Jetcarrier, a logistics and freight specialist, was a cornerstone of this transformation, intended to streamline the group’s B2B and B2C skincare distribution. However, the market’s hesitant response to the subsequent offering indicates that while institutional creditors are willing to swap debt for equity to support this pivot, smaller investors remain cautious about the company’s valuation or its near-term cash flow prospects.
The financial mechanics of the deal are now moving toward a final settlement. ABTEC expects to announce the definitive results on March 23, with the due date for payment set for March 25. For those who did participate, the new shares are scheduled to be delivered to VPS accounts around April 8, the same day they are expected to begin trading on Euronext Expand. This timeline provides a narrow window for the company to demonstrate that its integrated logistics and biotech model can deliver the synergies promised during the Jetcarrier merger.
The shortfall in the subsequent offering is unlikely to derail ABTEC’s immediate operations, given that the primary capital restructuring was achieved through the February private placement. Nevertheless, the 51.5% undersubscription serves as a signal of investor fatigue or skepticism. In a climate where U.S. President Trump’s administration has emphasized deregulation and market-driven growth, European micro-cap firms like ABTEC face increasing pressure to prove their commercial viability without relying on frequent dilutive equity raises.
The company’s future now hinges on its ability to convert its expanded logistics capabilities into higher margins for its sustainable skincare products. With the share capital increase expected to be registered with the Norwegian Register of Business Enterprises in early April, the focus shifts from the balance sheet to the income statement. The market will be watching closely to see if the "new" ABTEC can justify its NOK 5.00 subscription price through organic growth rather than further acquisitions.
Explore more exclusive insights at nextfin.ai.
